TLDR
- PSTV drops 4.80% as AMA grants CNSide CPT code approval boost
- AMA code 0640U strengthens CNSide reimbursement and adoption path
- CNSide gains billing clarity, supporting wider U.S. clinical rollout
- Plus Therapeutics expands CNS diagnostics with AMA-backed code
- New CPT code enhances CNSide tracking, adoption, and revenue growth
Plus Therapeutics (PSTV) traded at $3.17, down 4.80%, after a sharp intraday decline and weak consolidation near session lows. The company secured a new AMA-approved billing code for its CNSide diagnostic platform. The update strengthens its commercial pathway despite short-term market pressure.
AMA Code Approval Strengthens Reimbursement Pathway
Plus Therapeutics, Inc. secured a Proprietary Laboratory Analyses CPT code for its CNSide CSF tumor cell test. The American Medical Association assigned code 0640U, which becomes effective on July 1, 2026. This approval creates a standardized billing framework for the company’s diagnostic offering.
The new code supports payer reimbursement processes and improves claims efficiency across healthcare systems. As a result, healthcare providers can submit claims with greater consistency and clarity. This structure reduces administrative friction and accelerates coverage decisions.
The approval aligns with the company’s ongoing U.S. commercial rollout of CNSide diagnostics. The company continues to expand access to its central nervous system cancer testing platform. Consequently, the reimbursement milestone strengthens its broader commercialization strategy.
CNSide Platform Drives Clinical Adoption and Market Expansion
CNSide focuses on detecting tumor cells in cerebrospinal fluid for patients with metastatic CNS cancers. The test supports clinicians managing complex conditions such as leptomeningeal metastases. Therefore, the platform addresses a critical need in oncology diagnostics.
The dedicated billing code simplifies ordering and billing processes for hospitals and cancer centers. This improvement encourages adoption among oncologists and neurologists across the United States. As usage increases, the platform gains stronger positioning within clinical workflows.
The PLA code enables national tracking of test utilization through claims data. This data supports real-world evidence development and health outcome analysis. Hence, the system strengthens long-term validation of the CNSide platform.
Commercial Strategy Expands Alongside Therapeutic Pipeline
Plus Therapeutics continues to scale its diagnostics segment alongside its radiopharmaceutical development programs. The CNSide platform plays a key role in its integrated approach to CNS cancer management. Diagnostics and therapeutics progress in parallel within its pipeline.
The reimbursement milestone enhances the company’s ability to generate revenue from diagnostic services. It also supports broader awareness among healthcare providers treating metastatic CNS conditions. The company strengthens its commercial footprint in precision oncology.
PSTV shares declined during the session due to broader selling pressure. However, the underlying business development signals continued progress in commercialization efforts. The company maintains focus on building CNSide into a sustainable and scalable diagnostic franchise.
